Physician profile
Matthew Harrison
NPI 1467016873
$1,287.11
in general payments reported to CMS, 2019-2025
17 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.46 · 2023: $286 · 2024: $591 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,270.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $397.69 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $149.49 | 2023-2025 | Eliquis, Camzyos |
| Lilly USA, LLC | $116.06 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $96.45 | 2023-2025 | |
| Sanofi Pasteur INC. | $72.52 | 2023 | |
| Novo Nordisk INC | $68.32 | 2024-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $63.17 | 2023-2024 | Trelegy Ellipta, Bexsero, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.64 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $46.46 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $42.28 | 2023 | Interstim |
| Inspire Medical Systems, INC. | $38.75 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $33.24 | 2024 | Spravato |
| Amgen INC. | $32.92 | 2024-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $29.82 | 2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $15.33 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.67 | 2024 | Farxiga |
| Merck Sharp & Dohme LLC | $14.30 | 2025 | Lagevrio, Vaxneuvance, Rotateq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.